The primary difference between Retatrutide and Zepbound is their formulation and approval status.
Zepbound (tirzepatide) is a dual-hormone agonist currently FDA-approved for weight loss. Retatrutide is an investigational “triple-agonist” medication still in Phase 3 clinical trials and is not yet commercially available.
While both medications are weekly injections developed by Eli Lilly to treat obesity, they differ in how they target the body’s metabolic pathways and the average weight loss achieved in clinical studies.
| Zepbound → At 15 mg, Zepbound-treated adults achieved an average weight reduction of almost 21% of their body weight. | Retatrutide → Delivered weight loss of up to an average of 71.2 lbs with 12 mg (maximum dose). |
|---|---|
How Do Retatrutide & Zepbound Work?
Both medications belong to a newer category of drugs called incretin-based therapies. They mimic hormones your body naturally produces after eating. These hormones affect things like:
✓ Hunger and fullness
✓ Blood sugar regulation
✓ Insulin release
✓ Digestion speed
✓ Energy use and fat metabolism
Zepbound (Tirzepatide): The Dual-Action Approach
Zepbound uses tirzepatide, which activates two hormone receptors:
GLP-1 (Glucagon-Like Peptide-1)
This is the pathway most people already know because of medications like Ozempic and Wegovy. GLP-1 helps:
- Reduce appetite
- Slow stomach emptying
- Improve satiety
- Stabilize blood sugar levels
A lot of the “I’m not constantly thinking about food anymore” effect comes from GLP-1 activity.
GIP (Glucose-Dependent Insulinotropic Polypeptide)
GIP is the second pathway. This pathway may help support fat metabolism and improve metabolic regulation. When tirzepatide combined both GLP-1 and GIP activity, it became one of the biggest breakthroughs in obesity treatment.
That combination eventually became Zepbound, which received FDA approval in November 2023 for chronic weight management. The same active ingredient is also sold as Mounjaro for the treatment of type 2 diabetes.
Retatrutide: The Triple-Agonist Approach
Retatrutide takes things one step further. Instead of targeting two hormone receptors, it targets three:
- GLP-1
- GIP
- Glucagon
GLP-1 and GIP mostly help reduce calorie intake by lowering appetite and helping people eat less. Glucagon appears to work from another angle. Glucagon receptor activation may help:
- Increase energy expenditure
- Raise thermogenesis (calorie burning)
- Mobilize stored fat
- Potentially increase metabolic output
So instead of only reducing how much energy comes in, Retatrutide may also increase how much energy the body uses.
Weight Loss Results: What Do the Studies Show?
In the clinical trials used for FDA approval, Zepbound showed extremely strong results. At the time, these results made tirzepatide one of the most effective FDA-approved weight loss medications ever studied. Participants using the highest dose (15mg weekly) lost:
| About 48 pounds on average | Roughly 21% of total body weight | Over a 72-week period |
|---|---|---|
At the beginning of the 72-week study, the average participant weighed 231 lbs (104.8 kg), had a BMI of 38, and nearly 95% met the medical definition for obesity.
Average Weight Loss Results:
- 5 mg dose: Lost an average of 15% of their body weight.
- 10 mg dose: Lost an average of 19.5% of their body weight.
- 15 mg dose: Lost an average of 20.9% of their body weight.
- Placebo group: Lost just 3.1% of their body weight.
An overwhelming majority of people taking the medication (85% to 91%, depending on the dose) lost at least 5% of their weight, compared to only 35% in the placebo group. More than half of the patients on the higher doses (10 mg and 15 mg) lost 20% or more of their total body weight. Only 3% of the placebo group hit this mark.
Retatrutide Weight Loss Results
Retatrutide’s Phase 2 trial results were even more aggressive. This level of response is unusually high.
At 48 weeks:
| Participants lost an average of 24.2% of body weight | Average weight loss was approximately 58 pounds |
|---|---|
- Ranging from 1 mg to 12 mg, patients achieved an average weight loss of up to 17.5%, which equals about 41.2 pounds (18.7 kg).
- By the end of the 48-week study, the results were even more significant. Patients taking the highest dose reached an average weight loss of up to 24.2%, shedding roughly 57.8 pounds (26.2 kg).
Dosing and Weekly Injections
Both medications are taken as once-weekly subcutaneous injections. The overall process is pretty similar: start low, increase slowly, and allow the body time to adjust.
Zepbound Dosing Schedule
Zepbound uses gradual dose escalation to reduce side effects. Typical progression:
- 2.5mg weekly for the first 4 weeks
- Increase to 5mg weekly
- Additional increases in 2.5mg increments every 4 or more weeks if tolerated
Available doses include:
- 2.5mg
- 5mg
- 7.5mg
- 10mg
- 12.5mg
- 15mg
Common maintenance doses are 5mg, 10mg, or 15mg weekly.
Retatrutide Dosing
Because Retatrutide is still investigational, official prescribing guidelines do not exist yet. In clinical trials, researchers studied doses ranging from:
- 1mg weekly
- Up to 12mg weekly
The strongest weight loss effects appeared at the higher 8mg to 12mg range. If approved, experts expect a similar slow-titration approach to minimize gastrointestinal side effects.
Side Effects of Retatrutide and Zepbound
The side effect profiles are actually fairly similar between the two medications. Most side effects involve the digestive system. For many people, these symptoms are strongest during dose increases and gradually improve over time.
Common side effects reported with both include:
- Nausea
- Diarrhea
- Constipation
- Vomiting
- Abdominal discomfort
- Indigestion (dyspepsia)
Important Zepbound Safety Warnings
Because Zepbound is already FDA-approved, its safety labelling is much more detailed. Alert your doctor right away if you notice any warning signs, including:
- A lump or swelling in your neck
- Hoarseness or changes in your voice
- Difficulty swallowing
- Shortness of breath
Do not take Zepbound if:
- You or anyone in your family has ever been diagnosed with Medullary Thyroid Carcinoma (MTC), a type of thyroid cancer.
- You have a genetic endocrine condition called Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
- You are allergic to tirzepatide or any other ingredient contained in the medication.
Retatrutide Safety So Far
Retatrutide’s long-term safety profile is still being studied. So far, Phase 2 trial data have shown:
- Similar GI-related side effects to other GLP-1-based medications
- Dose-dependent side effects
- Symptoms that often improve over time
- No major unexpected safety signals identified yet
Availability Is the Biggest Difference Right Now
Zepbound received FDA approval in November 2023 for chronic weight management. In 2024, it also received approval for obstructive sleep apnea in adults with obesity. Right now, it is:
- Available by prescription
- Accessible through healthcare providers
- Sometimes covered by insurance plans
- $300–$540 CAD/month without insurance coverage
Retatrutide, on the other hand, is currently in Phase 3 development through Eli Lilly’s TRIUMPH trial program. The medication has received FDA Fast Track designation for the treatment of obesity, which helps expedite the review process.
Current expectations suggest:
- Phase 3 trials may finish around mid-2026
- Earliest possible approval could happen around 2027
- Current access is mostly limited to clinical trial participants
Conclusion
Zepbound and Retatrutide are two of the most powerful obesity medications developed so far, but they’re at very different stages. That’s a big reason why so many researchers and clinicians are watching it closely.
Still, Retatrutide is not yet approved, and larger long-term studies are ongoing. Until those results are complete, Zepbound remains the more established option for people seeking treatment right now.
Whichever medication you are considering, the most important step is working with a qualified healthcare provider who can evaluate your medical history, discuss the risks and benefits, and help develop a realistic long-term weight management plan.
Frequently Asked Questions
Could these medications affect muscle mass during weight loss?
Yes, both Zepbound (tirzepatide) and the investigational drug Retatrutide cause a reduction in absolute muscle mass. In the pooled dataset for Zepbound’s SURMOUNT-1 trial, the total body weight lost, approximately 75%, came from fat mass and 25% was derived from lean mass. Analysis from the trial in Lancet Diabetes & Endocrinology found that approximately 38% of the weight lost was lean mass.
Why do dose increases happen so slowly when taking GLP-1?
The gradual titration process is mainly designed to reduce gastrointestinal side effects. Increasing too quickly can worsen nausea, vomiting, bloating, or abdominal discomfort. Slow escalation gives the digestive system and nervous system more time to adapt to the medication’s effects.
Can people develop tolerance to weight loss drugs?
Yes, people can experience what feels like a tolerance to medications like Zepbound and Retatrutide, but medically this is known as reaching a weight loss plateau. As you lose a significant amount of weight, your body naturally defends itself by slowing down your metabolism and burning fewer calories to preserve energy. Eventually, your lower calorie intake perfectly matches the fewer calories your smaller body needs to function. Over many months, your brain and gut receptors can become less sensitive to the medication’s hormones.
